학술논문
Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection
이용수 0
- 영문명
- 발행기관
- 대한안과학회
- 저자명
- Min Woo Kim Haein Moon Sung Jae Yang Soo Geun Joe
- 간행물 정보
- 『The Korean Journal of Ophthalmology』Vol.30 No.1, 25~31쪽, 전체 7쪽
- 주제분류
- 의약학 > 의학일반
- 파일형태
- 발행일자
- 2016.02.28
국문 초록
영문 초록
Purpose: To evaluate the effects of posterior subtenon triamcinolone acetonide injection on refractory diabetic macular edema (DME) after intravitreal bevacizumab (IVB) injection failure.
Methods: Patients with DME and central subfield thickness (CST) >300 μm who did not respond to IVB injections
were retrospectively included. Specifically, we enrolled patients who were diagnosed with refractory DME and who experienced an increase in CST after 1 to 2 IVB injections or no decrease after ≥3 consecutive IVB injections. One clinician injected 20 mg of triamcinolone acetonide into the posterior subtenon space. All patients received ophthalmic examinations at baseline and at 2, 4, and 6 months post-baseline. Examinations included Snellen visual acuity, intraocular pressure, and spectral-domain optical coherence tomography.
Results: Forty eyes of 34 patients were included. The average baseline CST was 476 μm. The average CST
decreased to 368 μm at 2 months, 374 μm at 4 months, and 427 μm at 6 months (p < 0.001 for all results, Wilcoxon
signed-rank test). The average intraocular pressure increased from 15.50 to 16.92 mmHg at 2 months but decreased to 16.30 mmHg at 4 months and 15.65 mmHg at 6 months. Logarithm of the minimum angle of resolution visual acuity improved from 0.56 to 0.50 at 2 months (p = 0.023), 0.50 at 4 months (p = 0.083), and 0.48 at 6 months (p = 0.133, Wilcoxon signed-rank test). No complications were detected.
Conclusions: Posterior subtenon triamcinolone acetonide is an effective and safe treatment for reducing CST
in DME refractory to IVB.
목차
Materials and Methods
Results
Discussion
Conflict of Interest
References
해당간행물 수록 논문
참고문헌
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!